WO2000015211A2
(fr)
*
|
1998-09-17 |
2000-03-23 |
Akesis Pharmaceuticals, Inc. |
Compositions et traitements contre les troubles du metabolisme du glucose
|
US6376549B1
(en)
*
|
1998-09-17 |
2002-04-23 |
Akesis Pharmaceuticals, Inc. |
Metforimin-containing compositions for the treatment of diabetes
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
JP2003535034A
(ja)
*
|
1999-11-12 |
2003-11-25 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法
|
US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
KR20100130651A
(ko)
*
|
1999-12-23 |
2010-12-13 |
노파르티스 아게 |
당 대사 장애를 치료하기 위한 혈당강하제의 용도
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
DK1741445T3
(da)
|
2000-01-21 |
2013-11-04 |
Novartis Ag |
Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
|
EP1254113A1
(fr)
*
|
2000-01-24 |
2002-11-06 |
Novo Nordisk A/S |
2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
HUP0301622A3
(en)
|
2000-07-04 |
2006-05-29 |
Novo Nordisk As |
Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
US20060089389A1
(en)
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
JP5161412B2
(ja)
|
2000-09-18 |
2013-03-13 |
サノス・バイオサイエンス・アクティーゼルスカブ |
Glp−1及びglp−2ペプチドの使用方法
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
CA2424964C
(fr)
|
2000-10-06 |
2007-12-04 |
Tanabe Seiyaku Co., Ltd. |
Composes azotes a noyau a cinq elements
|
UA74023C2
(en)
*
|
2000-11-10 |
2005-10-17 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
TWI243162B
(en)
*
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
EP1354882A1
(fr)
*
|
2000-12-27 |
2003-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de dipeptidyl peptidase iv
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
US7253172B2
(en)
|
2001-06-20 |
2007-08-07 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
AU2002344820B2
(en)
|
2001-06-20 |
2006-12-14 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
DE60223920T2
(de)
|
2001-06-27 |
2008-11-13 |
Smithkline Beecham Corp. |
Pyrrolidine als dipeptidyl-peptidase-inhibitoren
|
JP4357293B2
(ja)
|
2001-06-27 |
2009-11-04 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
|
WO2003002531A2
(fr)
*
|
2001-06-27 |
2003-01-09 |
Smithkline Beecham Corporation |
Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase
|
US6709651B2
(en)
*
|
2001-07-03 |
2004-03-23 |
B.M.R.A. Corporation B.V. |
Treatment of substance P-related disorders
|
UA74912C2
(en)
*
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
CA2464995A1
(fr)
*
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20030135663A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Sun Microsystems, Inc. |
Method, system, and program for including device parameters from a device driver in a configuration file
|
PL371678A1
(en)
|
2002-02-13 |
2005-06-27 |
F.Hoffmann-La Roche Ag |
Novel pyridin- and pyrimidin-derivatives
|
CA2474460C
(fr)
|
2002-02-13 |
2009-12-22 |
F. Hoffmann-La Roche Ag |
Derives de pyridine et de quinoline
|
EP1338595B1
(fr)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
|
US7307164B2
(en)
*
|
2002-03-25 |
2007-12-11 |
Merck & Co., Inc. |
β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
BR0311535A
(pt)
*
|
2002-06-03 |
2005-02-22 |
Novartis Ag |
Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas
|
US6710040B1
(en)
*
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
2型糖尿病治療剤
|
JPWO2004007446A1
(ja)
*
|
2002-07-10 |
2005-11-10 |
アステラス製薬株式会社 |
新規なアゼチジン誘導体又はその塩
|
DE60330485D1
(de)
*
|
2002-07-15 |
2010-01-21 |
Merck & Co Inc |
Zur behandlung von diabetes
|
TW200401635A
(en)
*
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
PL374732A1
(en)
*
|
2002-09-19 |
2005-10-31 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
|
CA2499586A1
(fr)
*
|
2002-10-07 |
2004-04-22 |
Merck & Co., Inc. |
Inhibiteurs de la dipeptidyl peptidase heterocyclique beta-amino utiles pour le traitement ou la prevention du diabete
|
PT1556362E
(pt)
*
|
2002-10-18 |
2008-06-16 |
Merck & Co Inc |
Compostos beta-amino heterocíclicos inibidores da dipeptidil peptidase para o tratamento ou prevenção da diabetes
|
BR0315796A
(pt)
|
2002-11-07 |
2005-09-13 |
Merck & Co Inc |
Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
|
US7309714B2
(en)
*
|
2002-12-04 |
2007-12-18 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20060052382A1
(en)
*
|
2002-12-20 |
2006-03-09 |
Duffy Joseph L |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
PL377847A1
(pl)
|
2003-01-14 |
2006-02-20 |
Arena Pharmaceuticals Inc. |
1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
|
JP4564952B2
(ja)
|
2003-01-17 |
2010-10-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体
|
CA2513684A1
(fr)
*
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
|
US20040242568A1
(en)
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
PE20081293A1
(es)
*
|
2003-04-16 |
2008-11-04 |
Novartis Ag |
Procedimiento de preparacion de compuestos 2(s)-cianopirrolidina n-(n'-glicilo sustituida)
|
GB0308854D0
(en)
*
|
2003-04-16 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
WO2004103993A1
(fr)
|
2003-05-14 |
2004-12-02 |
Syrrx, Inc. |
Inhibiteurs de dipeptidyl peptidase
|
US7560455B2
(en)
*
|
2003-05-14 |
2009-07-14 |
Merck & Co., Inc. |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
CN1798556A
(zh)
|
2003-06-06 |
2006-07-05 |
麦克公司 |
作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
|
EP1638950A4
(fr)
|
2003-06-17 |
2010-06-30 |
Merck Sharp & Dohme |
Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
|
SI1638970T1
(sl)
|
2003-06-20 |
2011-03-31 |
Hoffmann La Roche |
Derivati pirid (2, 1-a)-izokinolina kot inhibitorji dpp-iv
|
MXPA05013734A
(es)
|
2003-06-20 |
2006-03-08 |
Hoffmann La Roche |
Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
|
CA2533893A1
(fr)
|
2003-07-31 |
2005-02-10 |
Merck & Co., Inc. |
Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7790736B2
(en)
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7790734B2
(en)
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
AR046330A1
(es)
*
|
2003-09-09 |
2005-12-07 |
Japan Tobacco Inc |
Inhibidor de dipeptidilpeptidasa iv
|
WO2005033099A2
(fr)
*
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
|
ZA200603165B
(en)
*
|
2003-11-03 |
2007-07-25 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
CN1870990A
(zh)
*
|
2003-11-04 |
2006-11-29 |
默克公司 |
作为糖尿病治疗或预防用二肽基肽酶iv抑制剂的稠合苯基丙氨酸衍生物
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR100918322B1
(ko)
*
|
2003-11-12 |
2009-09-22 |
페노믹스 코포레이션 |
헤테로시클릭 보론산 화합물
|
JP2007511487A
(ja)
|
2003-11-17 |
2007-05-10 |
ノバルティス アクチエンゲゼルシャフト |
ジペプチジルペプチダーゼiv阻害剤の使用
|
US20080038341A1
(en)
|
2004-01-20 |
2008-02-14 |
James Kowalski |
Direct Compression Formulation And Process
|
EP1712547B1
(fr)
*
|
2004-02-05 |
2011-12-14 |
Kyorin Pharmaceutical Co., Ltd. |
Derive de bicycloester
|
CN1922139B
(zh)
*
|
2004-02-18 |
2010-12-29 |
杏林制药株式会社 |
双环酰胺衍生物
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CA2555399A1
(fr)
*
|
2004-02-20 |
2005-09-01 |
Novartis Ag |
Utilisation de composes organiques
|
EP1719757B1
(fr)
*
|
2004-02-27 |
2013-10-09 |
Kyorin Pharmaceutical Co., Ltd. |
Derive bicyclo
|
KR100844593B1
(ko)
*
|
2004-03-09 |
2008-07-07 |
내셔날 헬스 리서치 인스티튜트 |
피롤리딘 화합물
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN102134229B
(zh)
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
TW200604167A
(en)
*
|
2004-04-27 |
2006-02-01 |
Astellas Pharma Inc |
Pyrrolidine derivatives
|
WO2005108382A1
(fr)
*
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
|
CN1960990A
(zh)
*
|
2004-05-18 |
2007-05-09 |
默克公司 |
作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的环己基丙氨酸衍生物
|
WO2005118555A1
(fr)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
WO2005117861A1
(fr)
*
|
2004-06-04 |
2005-12-15 |
Novartis Ag |
Utilisation de composes organiques
|
EP1778220A1
(fr)
|
2004-07-12 |
2007-05-02 |
Phenomix Corporation |
Composes cyano contraints
|
WO2006019965A2
(fr)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidyl peptidase
|
WO2006012395A2
(fr)
|
2004-07-23 |
2006-02-02 |
Susan Marie Royalty |
Inhibiteurs de peptidase
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
AR050615A1
(es)
*
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
EP1799639B1
(fr)
*
|
2004-10-12 |
2013-09-04 |
Glenmark Pharmaceuticals S.A. |
Nouveaux inhibiteurs de dipeptidyle peptidase iv, compositions pharmaceutiques en contenant, et leur procédé de préparation
|
KR20070068407A
(ko)
*
|
2004-10-25 |
2007-06-29 |
노파르티스 아게 |
Dpp―iv 억제제, ppar 항당뇨병제 및메트포르민의 조합물
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
AU2005318597A1
(en)
|
2004-12-20 |
2006-06-29 |
F. Hoffmann-La Roche Ag |
4-aminopiperidine derivatives
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
WO2006068978A2
(fr)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
GT200600008A
(es)
*
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
WO2006090244A1
(fr)
*
|
2005-02-22 |
2006-08-31 |
Glenmark Pharmaceuticals S.A. |
Nouveaux derives d'adamantine utilises en tant qu'inhibiteurs de dipeptidyl peptidase iv, procedes de preparation associes, et compositions pharmaceutiques les contenant
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
ZA200708179B
(en)
|
2005-04-22 |
2009-12-30 |
Alantos Pharmaceuticals Holding Inc |
Dipeptidyl peptidase-IV inhibitors
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US20090317376A1
(en)
|
2005-06-06 |
2009-12-24 |
Georgetown University Medical School |
Compositions And Methods For Lipo Modeling
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
US20090149504A1
(en)
*
|
2005-06-17 |
2009-06-11 |
Aurigene Discovery Technologies Limited |
Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors
|
WO2007006790A2
(fr)
*
|
2005-07-12 |
2007-01-18 |
Novartis Ag |
Combinaison de composes organiques
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
KR20080031936A
(ko)
*
|
2005-08-04 |
2008-04-11 |
노파르티스 아게 |
빌다글립틴의 염
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
PL1942898T5
(pl)
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JP2009510134A
(ja)
*
|
2005-10-07 |
2009-03-12 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
JP2009522374A
(ja)
*
|
2006-01-06 |
2009-06-11 |
ノバルティス アクチエンゲゼルシャフト |
糖尿病処置のためのビルダグリプチンの使用
|
AU2007224066B2
(en)
|
2006-03-08 |
2011-10-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
WO2007109354A2
(fr)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
|
WO2007112347A1
(fr)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
DK2004601T3
(da)
*
|
2006-04-03 |
2011-06-27 |
Matrix Lab Ltd |
Nye dipeptidylpeptidase-IV-inhibitorer samt fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
|
CA2682846C
(fr)
*
|
2006-04-03 |
2015-05-12 |
Matrix Laboratories Ltd. |
Nouveaux inhibiteurs de la dipeptidyl peptidase iv et procedes pour la preparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci
|
UA97479C2
(ru)
|
2006-04-11 |
2012-02-27 |
Арена Фармасьютикалз, Инк. |
Применение g-белок-связанного рецептора (gpcr) для идентификации средств, которые усиливают секрецию глюкозозависимого инсулинотропного пептида (gi)
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
AU2007267833B2
(en)
|
2006-05-26 |
2012-07-26 |
Amylin Pharmaceuticals, Llc |
Composition and methods for treatment of congestive heart failure
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
GEP20125701B
(en)
*
|
2006-09-13 |
2012-12-10 |
Takeda Pharmaceuticals Co |
Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US20080167479A1
(en)
*
|
2007-01-10 |
2008-07-10 |
Medichem, S.A. |
Process for preparing vildagliptin
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
ATE550319T1
(de)
|
2007-03-22 |
2012-04-15 |
Kyorin Seiyaku Kk |
Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
|
CN103330939A
(zh)
|
2007-04-03 |
2013-10-02 |
田边三菱制药株式会社 |
二肽基肽酶iv抑制化合物和甜味剂的并用
|
DE102007022007A1
(de)
*
|
2007-05-08 |
2008-11-13 |
Schebo Biotech Ag |
Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
|
KR101560844B1
(ko)
|
2007-06-04 |
2015-10-15 |
벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 |
트라이-아릴계 화합물 및 이를 포함하는 조성물
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
EP3542801A1
(fr)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Dérivés de la purine destinés à être utilisés dans le traitement de maladies associées à fab
|
US8338450B2
(en)
*
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
US20090082420A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched vildagliptin
|
US8598314B2
(en)
*
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
AU2008328845C1
(en)
*
|
2007-11-30 |
2012-11-08 |
Novartis Ag |
Organic compounds
|
MX2010006110A
(es)
|
2007-12-12 |
2010-06-25 |
Astrazeneca Ab |
Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
|
AU2008341352B2
(en)
|
2007-12-21 |
2013-08-01 |
Lg Chem, Ltd. |
Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(fr)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2009155309A1
(fr)
*
|
2008-06-19 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Dérivés substitués de cyanopyrrolidine
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
CA2732984A1
(fr)
*
|
2008-08-07 |
2010-02-11 |
Kyorin Pharmaceutical Co., Ltd. |
Procede de fabrication d'un derive de bicyclo[2.2.2]octylamine
|
CA2733778A1
(fr)
*
|
2008-08-14 |
2010-02-18 |
Hiroshi Uchida |
Composition pharmaceutique stabilisee
|
PE20110297A1
(es)
|
2008-08-15 |
2011-05-26 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 para la cicatrizacion de heridas
|
CZ2008512A3
(cs)
|
2008-08-26 |
2010-03-10 |
Zentiva, A. S |
Zpusob prípravy vysoce cistého vildagliptinu
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
CN102850330B
(zh)
*
|
2008-09-23 |
2014-10-15 |
成都地奥制药集团有限公司 |
经溴代的制备n取代的吡咯烷衍生物的方法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
PL2376447T3
(pl)
|
2009-01-09 |
2018-04-30 |
Orchid Pharma Limited |
Inhibitory dipeptydylopeptydazy iv
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
NZ594044A
(en)
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
WO2010092125A1
(fr)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabétique et ses utilisations
|
CN102438617A
(zh)
|
2009-03-27 |
2012-05-02 |
杏林制药株式会社 |
含有碱性添加剂的基质型缓释制剂
|
JP2012526093A
(ja)
|
2009-05-07 |
2012-10-25 |
アストラゼネカ・アクチエボラーグ |
置換1−シアノエチルヘテロシクリルカルボキサミド化合物750
|
CN102459247B
(zh)
|
2009-05-15 |
2014-09-17 |
诺华股份有限公司 |
作为醛固酮合酶抑制剂的苯并噁唑酮衍生物
|
JP5659224B2
(ja)
|
2009-05-15 |
2015-01-28 |
ノバルティス アーゲー |
アルドステロンシンターゼ阻害剤としてのアリールピリジン
|
AU2010251967B9
(en)
|
2009-05-28 |
2014-04-03 |
Novartis Ag |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
SG176010A1
(en)
|
2009-05-28 |
2011-12-29 |
Novartis Ag |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
US8748457B2
(en)
|
2009-06-18 |
2014-06-10 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
WO2011014520A2
(fr)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
|
WO2011012322A2
(fr)
|
2009-07-31 |
2011-02-03 |
Krka, D.D., Novo Mesto |
Synthèse et utilisation de vildagliptine pour préparer des formes galéniques pharmaceutiques
|
RU2550508C2
(ru)
|
2009-09-02 |
2015-05-10 |
Мерк Шарп И Доум Корп. |
Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
|
CN102656163B
(zh)
|
2009-09-03 |
2016-01-13 |
拜奥埃内杰尼克斯公司 |
抑制pask的杂环化合物
|
CA2774015A1
(fr)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
Conjugue de cdp-camptothecine, composition a distribution des orientations de particules et leurs utilisations
|
EP2295083A1
(fr)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Composition pharmaceutique renfermant les agents actifs metformine et sitagliptine ou vildagliptine
|
HUP0900638A2
(en)
|
2009-10-07 |
2011-05-30 |
Egyt Gyogyszervegyeszeti Gyar |
Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
|
CA2774573A1
(fr)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Composes et compositions comme modulateurs de l'activite de gpr119
|
EP2308847B1
(fr)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Pyridines substituées servant d'inhibiteurs de dipeptidyl-peptidase IV et leurs application pour le traitement du diabète et des maladies associées
|
ES2663351T3
(es)
|
2009-11-17 |
2018-04-12 |
Novartis Ag |
Derivados de aril-piridina como inhibidores de la aldosterona sintasa
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
CN102781237A
(zh)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
JP5575913B2
(ja)
|
2009-11-30 |
2014-08-20 |
ノバルティス アーゲー |
アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
WO2011078101A1
(fr)
|
2009-12-22 |
2011-06-30 |
塩野義製薬株式会社 |
Dérivé d'adamantanamine
|
WO2011090940A1
(fr)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Polymères à base de cyclodextrine pour administration thérapeutique
|
EP2538783B1
(fr)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
|
CN101798270B
(zh)
*
|
2010-02-25 |
2013-04-17 |
东华大学 |
一种3-氨基-1-金刚烷醇的制备方法
|
WO2011113947A1
(fr)
|
2010-03-18 |
2011-09-22 |
Boehringer Ingelheim International Gmbh |
Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
|
MX2012011631A
(es)
|
2010-04-06 |
2013-01-18 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
|
WO2011138421A1
(fr)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combinaison thérapeutique
|
WO2011146358A1
(fr)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
CN101870671B
(zh)
*
|
2010-06-11 |
2012-06-27 |
漆又毛 |
金刚烷基吡咯烷衍生物及制备和应用
|
EP3366304B1
(fr)
|
2010-06-24 |
2020-05-13 |
Boehringer Ingelheim International GmbH |
Traitement du diabète
|
IT1400714B1
(it)
|
2010-07-06 |
2013-06-28 |
Chemelectiva S R L |
Processo ed intermedi per la preparazione di un principio attivo.
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
TWI511958B
(zh)
|
2010-08-09 |
2015-12-11 |
Shionogi & Co |
胺基金剛烷胺基甲酸酯衍生物之製造方法
|
HU231050B1
(hu)
|
2010-08-19 |
2020-02-28 |
Egis Gyógyszergyár Nyrt. |
Eljárás gyógyszerhatóanyag előállítására
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
TR201010683A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San. Ve Ti̇c. A.Ş. |
Vildagliptin formülasyonları.
|
TR201107482A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San.Ve Ti̇c.A.Ş. |
Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
|
TR201101809A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Vildagliptin ve glimepirid kombinasyonları.
|
EP2468268B1
(fr)
|
2010-12-21 |
2017-12-13 |
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Composition de combinaison de vildagliptine et de gliclazide
|
UA110813C2
(uk)
|
2011-01-31 |
2016-02-25 |
Каділа Хелткере Лімітед |
Лікування ліподистрофії
|
CN103459382B
(zh)
|
2011-03-02 |
2016-06-29 |
拜奥埃内杰尼克斯公司 |
用于抑制pask的杂环化合物
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145361A1
(fr)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012145604A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012145603A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
WO2012170702A1
(fr)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
|
US9051329B2
(en)
|
2011-07-05 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
WO2013010964A1
(fr)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Quinazolines substituées, la préparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
|
US20140302150A1
(en)
|
2011-09-07 |
2014-10-09 |
Umit Cifter |
Dpp-iv inhibitor formulations
|
EP2572704A1
(fr)
|
2011-09-22 |
2013-03-27 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Formulations orodispersibles de la vildagliptine
|
ES2487271T3
(es)
|
2011-10-06 |
2014-08-20 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulaciones de dosificación sólidas inhibidoras de DPP-IV
|
WO2013055910A1
(fr)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
ITMI20112224A1
(it)
|
2011-12-06 |
2013-06-07 |
Chemelectiva S R L |
Nuovo processo ed intermedi per la sintesi di vildagliptin
|
CN102491928A
(zh)
*
|
2011-12-13 |
2012-06-13 |
临海天宇药业有限公司 |
一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
US9073930B2
(en)
|
2012-02-17 |
2015-07-07 |
Merck Sharp & Dohme |
Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CN102617434B
(zh)
*
|
2012-03-29 |
2014-07-23 |
中国科学院上海有机化学研究所 |
一锅法制备维达列汀
|
IN2012MU01383A
(fr)
*
|
2012-05-04 |
2014-02-28 |
|
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
WO2014018350A1
(fr)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
|
WO2014020462A1
(fr)
*
|
2012-08-01 |
2014-02-06 |
Alembic Pharmaceuticals Limited |
Procédé amélioré pour la préparation d'intermédiaire de la vildagliptine
|
WO2014052619A1
(fr)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
WO2014074668A1
(fr)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
CN103922986B
(zh)
*
|
2013-01-16 |
2017-02-15 |
上海彩迩文生化科技有限公司 |
维大列汀及其类似物、中间体及其制备方法和应用
|
JP6295277B2
(ja)
|
2013-02-14 |
2018-03-14 |
ノバルティス アーゲー |
Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
|
CN105377246B
(zh)
|
2013-04-22 |
2018-03-20 |
卡迪拉保健有限公司 |
针对非酒精性脂肪性肝病(nafld)的新组合物
|
WO2014195967A2
(fr)
|
2013-05-30 |
2014-12-11 |
Cadila Healthcare Limited |
Procédé de préparation de pyrroles présentant des activités hypocholestérolémiques hypolipidémiques
|
CN103304502B
(zh)
*
|
2013-06-02 |
2015-03-04 |
张远强 |
一类抗糖尿病化合物、其制备方法和用途
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
KR20160031551A
(ko)
|
2013-07-25 |
2016-03-22 |
노파르티스 아게 |
심부전의 치료를 위한 시클릭 폴리펩티드
|
IN2013MU02470A
(fr)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
AU2014293387B2
(en)
|
2013-07-25 |
2017-04-20 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
US10112898B2
(en)
|
2013-09-06 |
2018-10-30 |
Cadila Healthcare Limited |
Process for the preparation of saroglitazar pharmaceutical salts
|
EA201690938A1
(ru)
|
2013-11-05 |
2016-11-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
|
CN103641761A
(zh)
*
|
2013-11-22 |
2014-03-19 |
沈阳化工大学 |
一种维格利汀的制备方法
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
EA201691793A1
(ru)
|
2014-03-06 |
2016-12-30 |
Сановель Илач Санайи Ве Тиджарет А.Ш. |
Способ получения состава на основе вилдаглиптина в атмосфере инертного газа
|
CN103992257B
(zh)
*
|
2014-05-16 |
2016-03-30 |
苏州天马精细化学品股份有限公司 |
一种维格列汀粗品的纯化方法
|
CN105439873A
(zh)
*
|
2014-08-20 |
2016-03-30 |
天津药物研究院 |
3-羟基-1-金刚烷胺的制备方法
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
CN105884669B
(zh)
*
|
2014-09-15 |
2020-05-15 |
深圳翰宇药业股份有限公司 |
制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
CN104529857B
(zh)
*
|
2015-01-13 |
2016-03-30 |
佛山市赛维斯医药科技有限公司 |
卤代金刚烷酰胺类衍生物、其制备方法和用途
|
EA201791668A1
(ru)
|
2015-01-23 |
2017-11-30 |
Новартис Аг |
Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
CN104761456B
(zh)
*
|
2015-03-10 |
2020-04-10 |
上海威智医药科技有限公司 |
3-氨基-1-金刚烷醇的制备方法
|
CN104817482B
(zh)
*
|
2015-03-17 |
2017-05-10 |
宁波百思佳医药科技有限公司 |
2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
|
SI3310760T1
(sl)
|
2015-06-22 |
2023-02-28 |
Arena Pharmaceuticals, Inc. |
Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
RU2628573C2
(ru)
*
|
2015-11-27 |
2017-08-21 |
Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" |
Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа
|
WO2017115252A1
(fr)
|
2015-12-28 |
2017-07-06 |
Wockhardt Limited |
Composition pharmaceutique osmotique orale de vildagliptine
|
EP3468562A1
(fr)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinaisons de linagliptine et de metformine
|
DE102016116130A1
(de)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Verfahren zur Herstellung chiraler Aminonitrile
|
PL3512505T3
(pl)
|
2016-09-16 |
2023-08-07 |
Galenicum Health S.L.U. |
Farmaceutyczne kompozycje wildagliptyny
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
ES2894261T3
(es)
|
2016-12-09 |
2022-02-14 |
Cadila Healthcare Ltd |
Tratamiento de la colangitis biliar primaria
|
WO2018162722A1
(fr)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
GR1009406B
(el)
|
2017-10-03 |
2018-11-26 |
Φαρματεν Αβεε |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
KR102622198B1
(ko)
|
2018-03-30 |
2024-01-09 |
한미약품 주식회사 |
빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
|
GR1009644B
(el)
|
2018-09-25 |
2019-11-12 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
|
CN113166204A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽
|
CN113166101A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状五聚体化合物
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
JP7461735B2
(ja)
*
|
2019-12-02 |
2024-04-04 |
日本ジェネリック株式会社 |
ビルダグリプチン含有錠剤
|
CN113527167B
(zh)
*
|
2020-04-14 |
2024-01-19 |
威智医药股份有限公司 |
一种维格列汀的生产方法
|
WO2021234430A1
(fr)
|
2020-05-17 |
2021-11-25 |
Lotus International Pte. Ltd. |
Forme galénique à libération modifiée comprenant de la vildagliptine et son procédé de fabrication
|
WO2022003405A1
(fr)
|
2020-07-03 |
2022-01-06 |
Savoi Guilherme |
Procédé monotope permettant d'obtenir un composé intermédiaire pyrrolidine-2-carbonitrile et procédé télescopique à l'échelle industrielle permettant de préparer du (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptine) l'utilisant
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
CA3209219A1
(fr)
*
|
2021-01-21 |
2022-07-28 |
The Scripps Research Institute |
Regulateurs a petites molecules de proliferation cellulaire de type 2 alveolaire pour le traitement de maladies pulmonaires
|
WO2023084449A1
(fr)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Dérivés diaminocyclopentylpyridines pour le traitement d'une maladie ou d'un trouble
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|